Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001019056-25-000075·Adaptimmune Therapeutics PLC
Schedule 13G ownership disclosure
ADAPTIMMUNE THERAPEUTICS PLC
American Depositary Shares, each representing 6 Ordinary Shares · CUSIP: 00653A107
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- LONG FOCUS CAPITAL MANAGEMENT, LLC
Shares: 20,494,393.00 · Class: 8.0%
- LONG FOCUS CAPITAL MASTER, LTD.
Shares: 13,354,858.00 · Class: 5.2%
- CONDAGUA, LLC
Shares: 7,139,535.00 · Class: 2.8%
- JOHN HELMERS
Shares: 20,494,393.00 · Class: 8.0%
- GLENN HELMERS
Shares: 7,139,535.00 · Class: 2.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001019056-25-000075
- Form type
- SCHEDULE 13G/A
- Filer
- Adaptimmune Therapeutics PLC
- CIK
- CIK 1621227
- Filed
- Feb 11, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership